Last reviewed · How we verify
ropinirole IR
Ropinirole IR works by activating dopamine receptors in the brain, increasing dopamine levels and helping to alleviate symptoms of Parkinson's disease.
Ropinirole IR works by activating dopamine receptors in the brain, increasing dopamine levels and helping to alleviate symptoms of Parkinson's disease. Used for Parkinson's disease, Restless legs syndrome.
At a glance
| Generic name | ropinirole IR |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Dopamine agonist |
| Target | Dopamine receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Ropinirole IR is a dopamine agonist that directly stimulates dopamine receptors in the brain, mimicking the action of dopamine and helping to alleviate symptoms of Parkinson's disease, such as tremors, stiffness, and bradykinesia. This is in contrast to levodopa, which is converted to dopamine in the brain. By directly activating dopamine receptors, ropinirole IR can provide more consistent and predictable results.
Approved indications
- Parkinson's disease
- Restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Headache
- Fatigue
- Dyskinesia
Key clinical trials
- Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) (PHASE3)
- Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration) (PHASE2)
- Ropinirole Tablets In Young Patients With Restless Legs Syndrome (PHASE1)
- A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's (PHASE3)
- An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease (PHASE3)
- Long-term Study Of Ropinirole In Restless Legs Syndrome (PHASE4)
- Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease (PHASE3)
- RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |